Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Electronic Stakeholder Insight: Insulin Use in Type 2 Diabetes - From Last Resort to Early Intervention Datamonitor, May 2004, Pages: 238   Description     Table of Contents        Enquire before Buying    Send to a Friend   Only 13-28% of drug-treated type 2 diabetes patients receive insulin therapy. The late initiation of insulin reflects the general trend that it is a last resort therapy in the treatment of type 2 diabetes. We believe that there will be a shift towards earlier initiation of insulin in the future, along with increased uptake, following the introduction of non-injected insulin. Scope Analysis of interviews with 388 physicians in the 7 major markets, validated via in-depth interviews with international experts Determination of the prevalence of type 1 and type 2 diabetes, with forecasts to 2012 Analysis of the use of insulin therapy in the treatment of type 2 diabetes by line of therapy and evaluation of early vs. late initiation of insulin Assessment of the potential patient population for non-injected insulin: evaluation of switch from injected insulin and add-on to OAD therapy Highlights Due to rising rates of obesity and the aging population, type 2 diabetes is an emerging epidemic: We estimate there will be 50.1m diabetics in the seven major markets in 2012. Despite the large patient population, Our physician research reveals that only 50% of type 2 diabetics across the seven major markets are diagnosed. The late initiation of insulin reflects the trend that insulin is a therapy of last resort in the treatment of type 2 diabetes. Although some experts believe that the earlier initiation of insulin is emerging, additional clinical trials are required to support this strategy. Non-injected insulins are expected to overcome the key unmet need in the insulin market by providing a more convenient mode of administration, and they are also expected to increase the overall use of insulin in type 2 diabetes patients and shorten the time to initiation. Reasons to Purchase Understand the factors limiting the use of insulin in type 2 diabetes, based on both physician and patient perception Validate product forecasting based on diagnosis and treatment rates, and the estimated future use of insulin in the treatment of type 2 diabetes Recognize lucrative target populations, in terms of unmet need and patient potential, in order to successfully position developmental products Customers who bought this item also bought Metabolic Syndrome: New Opportunities in Diagnostics and Therapeutics The Diabetes Market Outlook: Market Analysis of Future Growth and Leading Players by Sector Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Commercial Perspectives: Diabetes - Type 2 Epidemic Driving Aggressive Therapy Metabolic Diseases Pipeline Analysis:Focus on Dyslipidemia, Diabetes, and Obesity Diabetes for Dummies, UK Edition The Impact of Islet Cell Transplantation on the Type 1 Diabetes Market September 29, 2005 The Metabolic Syndrome

		Top of page

All rights reserved. Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster